Company intelligence / Profile preview

IgGenix

South San Francisco, California, United Statesiggenix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IgGenix has advanced its lead candidate IGNX001, a first-in-class monoclonal antibody for peanut allergy, into a Phase 1 clinical trial ("ACCELERATE Peanut Study") to evaluate safety and tolerability. The company has presented supporting data at major conferences and continues to expand its pipeline targeting food and environmental allergies using its proprietary SEQ SIFTER™ platform. No efficacy results have been published yet as the program remains early-stage.

Therapeutic areas: ImmunologyDermatology
Modalities: Monoclonal antibodies (mAbs)Engineered human IgG antibodies derived from allergen-specific IgE B cells
Industry: Biotech

Drug pipeline

2 assets

IGNX001

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on IgGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgGenix.

Explore the full profile